Fundraising FoxAtlyphe
1 known investors
Find your way into Atlyphe
Sign up to see every warm intro you have to Atlyphe
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Atlyphe team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Zürich biotech developing targeted immunotherapy (ALY117) for stem cell transplantation and cancer.
Founders & leadership
MM
Maddalena MarconatoFounderMarconato is a physician-scientist with board certifications in clinical immunology and hematology who has led translational research projects in novel immunotherapies and early-phase clinical trials. She founded Atlyphe, a Zürich-based biotech company developing targeted immunotherapy for stem cell transplantation and cancer.
Investors · 1
Kickfundlisted by KickfundBasel · $950K
How we know: Kickfund's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Atlyphe do?
- Zürich biotech developing targeted immunotherapy (ALY117) for stem cell transplantation and cancer.
- Who founded Atlyphe?
- Atlyphe was founded by Maddalena Marconato.
- Who are Atlyphe's investors?
- Atlyphe's investors include Kickfund.